Harrow Acquires Melt Pharmaceuticals – Pharma Deal
- here's a breakdown of the details from the provided text, focusing on MELT-300:
- * Its a sublingually (under the tongue) delivered medication.
- * Superiority: MELT-300 was statistically superior too both sublingual midazolam alone (P = .009) and placebo (P
here’s a breakdown of the details from the provided text, focusing on MELT-300:
What is MELT-300?
* Its a sublingually (under the tongue) delivered medication.
* It’s a fixed dose combination of 3mg midazolam and 50mg ketamine.
* It’s designed for rapid sedation and pain relief.
Key Findings from the LOUISE Study (Phase 3):
* Superiority: MELT-300 was statistically superior too both sublingual midazolam alone (P = .009) and placebo (P <.0001).
* Reduced Rescue Sedation: Patients receiving MELT-300 required rescue sedation less ofen than those receiving sublingual midazolam (nearly twice as many needed rescue sedation with midazolam alone; P = .003).
Safety:
* A cardiac safety study showed MELT-300 did not alter normal heart rhythm.
Potential Impact (according to Mark L. Baum):
* Opioid Reduction: MELT-300 could significantly reduce or eliminate the need for opioids (specifically fentanyl) during cataract surgery.This is meaningful as even a single exposure to fentanyl can lead to addiction.
* IV Sedation Option: It could replace the need for IV sedation in cataract surgery.
* Broader Request: It has the potential to improve patient experiences and reduce opioid use in a variety of office-based and outpatient procedures beyond cataract surgery.
Source:
* The information comes from a Harrow press release and statements by Mark L.Baum to Healio.
* Published by Healio/Ophthalmology Times.